Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Gain Therapeutics ( (GANX) ) is now available.
On June 30, 2025, Gain Therapeutics announced progress in its Phase 1b clinical study for GT-02287, a treatment for Parkinson’s Disease. The study reached its participant target despite delays, and no serious adverse events were reported. Faster enrollment allows for earlier biomarker analysis, with full results expected in Q4 2025, ahead of schedule. The company is extending the screening window for participants in Australia and plans to engage local health authorities to extend the dosing period.
The most recent analyst rating on (GANX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Gain Therapeutics stock, see the GANX Stock Forecast page.
Spark’s Take on GANX Stock
According to Spark, TipRanks’ AI Analyst, GANX is a Neutral.
Gain Therapeutics is currently challenged by significant financial difficulties, with no revenue growth and persistent losses impacting profitability. These weaknesses heavily weigh down the stock score. Despite these challenges, technical analysis shows mixed signals, and recent positive corporate events related to Parkinson’s treatment offer some hope for future prospects. However, the negative valuation metrics further underscore the risks, leading to an overall cautious outlook.
To see Spark’s full report on GANX stock, click here.
More about Gain Therapeutics
Gain Therapeutics, Inc. operates in the biotechnology industry, focusing on developing innovative therapies for neurodegenerative diseases. The company is known for its work on small molecule therapies targeting protein misfolding, with a particular emphasis on diseases like Parkinson’s.
Average Trading Volume: 282,301
Technical Sentiment Signal: Hold
Current Market Cap: $58.99M
See more insights into GANX stock on TipRanks’ Stock Analysis page.